NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|October 7, 2024

Mechanism of Action of BiTE Immunotherapy

Author(s)Joshua K. Sabari, MD

Joshua K. Sabari, MD, discusses how tarlatamab, a BiTE, demonstrates a unique mechanism of action by targeting DLL3, which is aberrantly expressed in 85% to 94% of SCLC cells, thereby directing T cells to these cancer cells independently of MHC class I and promoting T-cell–mediated tumor lysis and regression.

Episodes in this series

EP. 1 Clinical Impressions and Therapy Goals

EP. 1 Clinical Impressions and Therapy Goals

EP. 2 Considerations for Extended Chemoimmunotherapy

EP. 2 Considerations for Extended Chemoimmunotherapy

EP. 3 Prophylactic Cranial Irradiation Considerations

EP. 3 Prophylactic Cranial Irradiation Considerations

EP. 4 Mechanism of Action of BiTE Immunotherapy

EP. 4 Mechanism of Action of BiTE Immunotherapy

EP. 5 Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes

EP. 5 Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes

EP. 6 Significance of Durable Responses in DeLLphi-301 Trial

EP. 6 Significance of Durable Responses in DeLLphi-301 Trial

$EP. 7 Expectations for PFS and OS in Relapsed/Refractory SCLC$

EP. 7 Expectations for PFS and OS in Relapsed/Refractory SCLC

EP. 8 Future Potential in Combination Therapies

EP. 8 Future Potential in Combination Therapies

EP. 9 Dual Maintenance With BiTE and PD-L1 Inhibitors

EP. 9 Dual Maintenance With BiTE and PD-L1 Inhibitors

EP. 10 B7-H3 Mechanism and Therapeutic Potential

EP. 10 B7-H3 Mechanism and Therapeutic Potential

EP. 11 Current Practices in B7-H3 Testing

EP. 11 Current Practices in B7-H3 Testing

EP. 12 Interpreting IDeate-Lung02 Trial Outcomes

EP. 12 Interpreting IDeate-Lung02 Trial Outcomes

EP. 13 Comparing Dosing Schedules With Standard Therapies

EP. 13 Comparing Dosing Schedules With Standard Therapies

EP. 14 Potential Synergies With T-Cell Engagers

EP. 14 Potential Synergies With T-Cell Engagers

EP. 15 Prospects in First-Line and Maintenance Settings

EP. 15 Prospects in First-Line and Maintenance Settings

EP. 16 Mechanism of Action Compared With Other Alkylating Agents

EP. 16 Mechanism of Action Compared With Other Alkylating Agents

EP. 17 Efficacy in Platinum-Sensitive vs Platinum-Resistant SCLC

EP. 17 Efficacy in Platinum-Sensitive vs Platinum-Resistant SCLC

EP. 18 Comparative Efficacy and Future Directions in SCLC Treatment

EP. 18 Comparative Efficacy and Future Directions in SCLC Treatment

Video content above is prompted by the following:

Please discuss the unique mechanism of action of tarlatamab, a BiTE, and its treatment potential as subsequent therapy for SCLC that has progressed after platinum-based chemotherapy.

Newsletter

Stay up to date on practice-changing data in community practice.

Latest CME

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO; Cathy Eng, MD, FACP, FASCO; John P. Leonard, MD

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL

NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC

Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer

Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment

Amivantamab Shows Potential to Unlock Curative Surgery in Metastatic CRC